Quantcast
Last updated on April 16, 2014 at 16:54 EDT

Latest Acetylcholine Stories

2009-04-09 07:45:00

NEW YORK, April 9 /PRNewswire/ -- According to Drs. Timothy Salthouse and Eric R. Braverman, the effects of the brain's cognitive abilities become less effective as early as our mid-twenties. A recent study by Dr. Timothy Salthouse, a University of Virginia professor of psychology and the study's lead investigator, shows that people lose their full capacity to make rapid comparisons, remember unrelated information, and detect relationships. Dr. Eric R. Braverman, author of the New York...

2009-04-06 16:17:59

Nicotine isn't just addictive, it may also interfere with dozens of cellular interactions in the body, U.S. researchers suggest. Brown University researchers say the data could help scientists develop better treatments for various diseases. It opens several new lines of investigation, lead author Edward Hawrot says in a statement. Hawrot and a team that included graduate students William Brucker and Joao Paulo looked specifically at the alpha-7 nicotinic acetylcholine receptor in mouse brain...

2009-04-01 08:00:00

WATERTOWN, Mass., April 1, /PRNewswire/ -- EnVivo Pharmaceuticals today announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of its lead product candidate, EVP-6124, in Japan and several other Asian countries. EVP-6124 is EnVivo's novel alpha-7 nicotinic acetylcholine receptor agonist currently in development for cognition enhancement in patients with Alzheimer's disease and Schizophrenia. EnVivo recently reported positive results...

2009-03-24 09:18:54

-A tiny genetic mutation is the key to understanding why nicotine--which binds to brain receptors with such addictive potency--is virtually powerless in muscle cells that are studded with the same type of receptor. That's according to California Institute of Technology (Caltech) researchers, who report their findings in the March 26 issue of the journal Nature.By all rights, nicotine ought to paralyze or even kill us, explains Dennis Dougherty, the George Grant Hoag Professor of Chemistry at...

2009-02-10 09:15:24

A research team led by Northwestern University reports that insulin may slow or prevent the damage and memory loss caused by toxic proteins affiliated with Alzheimer's disease. The study shows how insulin shields memory-orming synapses from harm. The researchers looked at neurons taken from one of the brain's crucial memory centers, the hippocampus. They treated cells with insulin and rosiglitazone, a drug commonly used to treat type 2 diabetes. The cells are susceptible to damage caused by...

d5e5738c0dcb2e74463a0867aebaf17d1
2009-01-23 09:18:29

Duke University Medical System researchers have discovered there are differing taste pathways for nicotine, which could provide a new approach for future smoking-cessation products. "We learned some of nicotine's secrets," said Albino Oliveira-Maia, M.D., Ph.D., a postdoctoral fellow of the Duke Department of Neurobiology. "This is the first study to explore both the peripheral taste pathways activated by nicotine, and how these pathways are integrated in sensory areas of the brain." The...

2009-01-12 01:17:00

MADISON, Wis., Jan. 12 /PRNewswire/ -- Mithridion, Inc., a drug development company focusing on serious Central Nervous System disorders, including Alzheimer's disease (AD), announced today that it held an initial closing of $2.9 million in Series B Preferred Stock financing. The company will use the funds for the clinical development of MCD-386, its lead drug candidate, aimed at stopping or slowing down disease progression and improving memory and cognition in this devastating disorder....

368802e689ea992f70a4767d2b62435a1
2008-11-18 09:25:18

Scientists have identified a relationship between two proteins in the brain that has links to both nicotine addiction and autism. The finding has led to speculation that existing drugs used to curb nicotine addiction might serve as the basis for potential therapies to alleviate the symptoms of autism. The discovery identified a defining role for a protein made by the neurexin-1 gene, which is located in brain cells and assists in connecting neurons as part of the brain's chemical...

2008-10-21 15:00:28

SARASOTA, Fla., Oct. 21 /PRNewswire/ -- A team of world-renowned scientists today announced the launch of Archer Pharmaceuticals, Inc., a new company that will use modern technologies for the identification of novel treatments for Alzheimer's disease. Archer Pharmaceuticals, Inc., led by Chief Executive Officer Michael Mullan, M.B.B.S., Ph.D. and Chief Technical Officer Fiona Crawford, Ph.D., was created based on the groundbreaking research that their team has been conducting in Florida...

2008-10-03 12:00:27

REYKJAVIK, Iceland, Oct. 3 /PRNewswire-FirstCall/ -- deCODE genetics today announced the filing of an investigational new drug (IND) application for DG071, the company's novel small-molecule modulator of phosphodiesterase 4 (PDE4), with the US Food and Drug Administration (FDA). The compound is being developed as a new and potentially safer means of targeting PDE4 to combat memory loss and cognitive deficits associated with Alzheimer's disease and other disorders in which neural signaling...